Syschem (India) Ltd
Incorporated in 1993, Syschem (India) Limited manufactures Active Pharmaceuticals Ingredients (APIs) and bulk drugs.[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit |
Ratios
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Permanent Employees count ・Standalone data |
|
||||||||||
| Installed Production Capacity TPA ・Standalone data |
|||||||||||
| Production Volume MT ・Standalone data |
|||||||||||
| Export Sales as % of Total Revenue % ・Standalone data |
|||||||||||
| Number of Export Countries count ・Standalone data |
|||||||||||
| Number of Customers (Consumers and Traders) count ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Newspaper Advertisement
- Company published newspaper notice of Mr. Suninder Veer Singh's appointment as managing director after 33rd AGM approval.
-
Announcement Under Regulation 30: Update In Response To Settlement Agreement Entered Between Lotous Builder V.S Syschem(India) Limited
- Syschem paid Rs1.25 crore settlement to Lotus Builders; will seek NCLT withdrawal of pending matter.
-
Compliance _ As Per Regulation 32 Of SEBI(LODR), 2015 : Statement Of Deviation And Variations For The Quarter Ended 30Th September, 2026.
- Syschem reports no deviation in preferential issue proceeds for quarter ended 30 September 2026.
-
Board Meeting Outcome for Outcome Of The Board Meeting Dated 08-10-2026
- Suninder Veer Singh becomes Managing Director; Ranjan Jain becomes Whole-Time Director. Statutory auditor appointed for five years.
-
Update on board meeting
- Board meeting rescheduled from 26 October 2026 to 27 October 2026 at 11:00 AM.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Product Profile:[1]
API/ Intermediates:
** a) Amoxycillin Trihydrate
b) Ampicillin Trihydrate
c) Cloxacillin Sodium
d) Dicloxacillin Sodium
e) Flucloxacillin Sodium (For export only)
f) Cephalexin
g) Cefadroxil
h) **Distillation of Specialist Solvents – methonel, Acetonitrile, Ethyl Acetate, and THF